Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Follow-Up Questions
Eagle Pharmaceuticals Inc (EGRX) 的本益比是多少?
Eagle Pharmaceuticals Inc 的本益比是 1.3589
EGRX 股票的價格表現如何?
EGRX 的當前價格為 $3.06,在上個交易日 decreased 了 0%。
Eagle Pharmaceuticals Inc 的主要業務主題或行業是什麼?
Eagle Pharmaceuticals Inc 屬於 Biotechnology 行業,該板塊是 Health Care